✨ Free AI Report
Olema Pharmaceuticals, Inc.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research Olema Pharmaceuticals, Inc.
Company Research

Olema Pharmaceuticals, Inc.: Business Overview, Financials & Competitive Analysis

Olema Pharmaceuticals, Inc. scores 6/10 on the AskCyborg Cyborg Score (Solid). Well-positioned clinical-stage biotech with differentiated mechanism and bullish analyst consensus, pending Phase 3 trial readouts and potential 2027 FDA approval. Olema demonstrates solid clinical progress with pivotal Phase 3 trials underway and strong analyst sentiment (6 analysts rate Strong Buy). However, as a clinical-stage company with no commercial revenue.

What is Olema Pharmaceuticals, Inc.'s industry? Olema Pharmaceuticals, Inc. (olema.com) operates in Biopharmaceuticals - Oncology (Targeted Cancer Therapeutics). AskCyborg classifies Olema Pharmaceuticals, Inc. under Biopharmaceuticals - Oncology (Targeted Cancer Therapeutics) in its company registry.

Olema Pharmaceuticals is a clinical-stage biopharmaceutical company focusing on the discovery, development, and commercialization of therapies for women's cancers. The company is advancing palazestrant, an estrogen re...

6/ 10Solid

Cyborg Score thesis

Well-positioned clinical-stage biotech with differentiated mechanism and bullish analyst consensus, pending Phase 3 trial...

Read the full analyst-debate transcript →
Industry Biopharmaceuticals - Oncology (Targeted Cancer Therapeutics)
3 named competitors
4 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: October 19, 2026
AI-Generated Research
30+ Page Report

Get the Latest Olema Pharmaceuticals, Inc. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Analyst-debate audio for Olema Pharmaceuticals, Inc.

AskCyborg analysts argue the bull and bear cases for Olema Pharmaceuticals, Inc. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
What's in This Report
Olema Pharmaceuticals, Inc. OverviewStrategic ProfileCompetitive LandscapeIndustry ContextKey facts
Get Interactive Report Freeor start reading below

Olema Pharmaceuticals, Inc. Overview

Pro stress-test →

Olema Pharmaceuticals is a clinical-stage biopharmaceutical company focusing on the discovery, development, and commercialization of therapies for women's cancers. The company is advancing palazestrant, an estrogen receptor antagonist and selective ER degrader, through Phase 3 clinical trials for ER+/HER2- metastatic breast cancer. Strategic partnerships and multiple trial phases position Olema for potential FDA approval and market entry by 2027.

Strategic Profile

Pro stress-test →

Olema leverages advanced scientific methods to develop treatments addressing challenges of both wild-type and mutant estrogen receptor-positive diseases. Beyond palazestrant, the company is developing OP-3136, a KAT6 inhibitor being evaluated in combination with endocrine therapies to enhance anti-tumor efficacy. The company's precision medicine approach targets treatment resistance mechanisms in hormone-driven cancers.

Competitive Landscape

Pro stress-test →

Olema competes in the targeted oncology space against established players developing next-generation endocrine therapies for ER+ breast cancer. Competitors include large pharma companies with approved ER-targeted agents and other biotech firms in clinical development. Recent Roche Phase 3 results for giredestrant in early-stage breast cancer elevated competitive intensity, though Olema's dual-mechanism ER antagonist/degrader approach offers differentiation.

Industry Context

Olema Pharmaceuticals, Inc. operates in Biopharmaceuticals - Oncology (Targeted Cancer Therapeutics).

Key facts

Founded: 2006 · Headquarters: San Francisco, California · Employees: 116 · Revenue: $0 · Market cap: $0.6B

What the AI analysts debated

AI-generated and not independently verified: selected findings from the multi-agent debate on Olema Pharmaceuticals, Inc..

  • Lead candidate palazestrant in pivotal Phase 3 OPERA-01 trial for second/third-line ER+/HER2- metastatic breast cancer with updated efficacy data supporting frontline combination studies
  • November 2025 public offering of $218.5M raised capital to fund ongoing Phase 3 trials and commercial preparations
+2 more AI-generated counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • November 2025Closed $218.5M public stock offering to fund clinical development
  • November 2025Announced clinical trial agreement with Pfizer for palazestrant combination study
  • +2 moreTrack every material event for Olema Pharmaceuticals, Inc. as it happens. Explore monitoring →
Get alerted when Olema Pharmaceuticals, Inc. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

GiredestrantER antagonist in Phase 3 for early-stage breast cancer→Various CDK4/6 InhibitorsCombination partners and competitive alternatives in ER+/HER2- metastatic breast cancer→Next-generation Endocrine TherapiesClinical-stage and approved therapies for hormone receptor-positive breast cancer→

Compare Olema Pharmaceuticals, Inc. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Olema Pharmaceuticals, Inc. operates in Biopharmaceuticals - Oncology (Targeted Cancer Therapeutics). See how the rest of the sector scores on the Cyborg framework.

Browse Biopharmaceuticals - Oncology (Targeted Cancer Therapeutics) research →
NEW · MCP server

Ask your AI assistant about Olema Pharmaceuticals, Inc.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Olema Pharmaceuticals, Inc. and its top competitor on Cyborg Score”
“What did Olema Pharmaceuticals, Inc. do this quarter?”
“Is Olema Pharmaceuticals, Inc. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg research is made

⚔

AI analyst debate, not single-author opinion

Every report is generated by a panel of AI analysts arguing across 11 dimensions, so counter-arguments sit alongside the case. The debate is a reasoning process; it does not independently verify facts.

📊

Dated, not live

The Cyborg Score and recent developments reflect public sources as of the date shown and can miss or lag recent events. Check primary sources before relying on them.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The Cyborg Score is an AI-generated opinion under that framework, not a credit rating or an investment recommendation.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, and news flow, analysed by AI models. Read the methodology →

AI-generated research summary based on public sources; it may contain errors or omissions. Not investment advice. Not reviewed or endorsed by the companies covered. Report an error: legal@askcyborg.com · Terms of Service

Frequently asked questions

What does Olema Pharmaceuticals, Inc. do?+
Olema Pharmaceuticals is a clinical-stage biopharmaceutical company focusing on the discovery, development, and commercialization of therapies for women's cancers. The company is advancing palazestrant, an estrogen re...
What is Olema Pharmaceuticals, Inc.'s Cyborg Score?+
Olema Pharmaceuticals, Inc. has a Cyborg Score of 6/10 (Solid). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Olema Pharmaceuticals, Inc.'s main competitors?+
Named competitors include Giredestrant, Various CDK4/6 Inhibitors, Next-generation Endocrine Therapies. The full competitive landscape is in the AskCyborg report.
How can I get the full Olema Pharmaceuticals, Inc. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Olema Pharmaceuticals, Inc. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Olema Pharmaceuticals, Inc. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

Top-scored companies on AskCyborg

The strongest performers across the analyst-debate framework.

9Advantest Corporation9Anthropic9Apple Inc.9Applied Materials, Inc.9Arista Networks9Aritzia Inc.9ASML Holding N.V.9BAE Systems plc9Barrick Mining Corporation9Berkshire Hathaway Inc.